This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Peers Over the Counter

By early 2002, "after losing a protracted patent litigation," Schering-Plough changed its view, said the Tufts Center for Drug Development. "To expand the brand name's viability," Schering-Plough sought and received FDA approval for OTC Claritin.

OTC Claritin "represents an important new treatment option for the estimated 20 million Americans who currently choose to treat their allergies with a non-prescription medication," Schering-Plough said in November 2002 news release, after the FDA approved the drug. Claritin went over the counter shortly after Schering-Plough introduced a cousin, Clarinex, to the prescription market.

Neither Merck nor Bristol-Myers has said much about turning their cholesterol drugs into OTC products. Mevacor has long since lost patent protection; its U.S. sales are being swamped by generic competitors. Pravachol loses U.S. patent protection in April 2006. It is the third-ranked drug in the statin class of cholesterol drugs. Pfizer's (PFE - Get Report) Lipitor is the leader, followed by Merck's Zocor, which loses its U.S. patent in mid-2006.

Zocor is the world's first statin to be switched to OTC status, having reached U.K. pharmacies in July. "In general, the switch has been well-received in the U.K.," said Paula Fryans, senior cardiovascular analyst for Datamonitor.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BMY $60.82 1.32%
AZN $31.61 1.54%
MRK $54.95 0.97%
PFE $33.26 2.56%
AAPL $112.92 2.94%

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs